Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697127 | 0.82 | MTNR1A (0.48) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL3688184 | 0.71 | ROCK2 (0.54) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL5651807 | 0.70 | MTNR1A (0.50) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL4081621 | 0.70 | MTNR1A (0.64) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL2544860 | 0.69 | MTNR1A (0.61) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| Bromide SCHEMBL30402372 | 0.68 | MTNR1A (0.60) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL30511844 | 0.67 | MTNR1A (0.64) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL592246 | 0.67 | MTNR1A (0.67) | MTNR1AMTNR1BROCK2LMNAKDM4E | |
| SCHEMBL6559881 | 0.67 | MTNR1B (1.00) | MTNR1AMTNR1BKDM4ECYP1A2HTR1A | |
| Cyclopropane SCHEMBL28100553 | 0.67 | LMNA (0.91) | MTNR1AMTNR1BLMNAKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | MTNR1A 3313/4885MTNR1B 2889/4885ROCK2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.